An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function

Cindy L. O'Bryant, Paul Haluska, Lee Rosen, Ramesh K. Ramanathan, Balaji Venugopal, Stephen Leong, Ramesh Boinpally, Amy Franke, Karsten Witt, Jeffry Evans, Chandra Belani, S. Gail Eckhardt, Suresh Ramalingam

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Purpose: To compare the pharmacokinetic (PK) parameters of a single dose of erlotinib in cancer patients with moderate hepatic impairment (MHI) to those of cancer patients with adequate hepatic function (AHF). Methods: Cancer patients with either AHF or MHI were treated with a single 150 mg dose of erlotinib on day 1 only followed by 96 h of plasma sampling for PK assessment. From day 5, patients were allowed to continue daily erlotinib in a maintenance phase. Non-smoking patients were stratified into an AHF cohort (total bilirubin ≤ upper limit of normal [ULN] and ALT/AST ≤ 1.5 X ULN) or a MHI cohort (Child-Pugh score of 7-9). The frequency of adverse events and laboratory changes were assessed. Results: Thirty-six patients, 21 with AHF and 15 with MHI, received at least one dose of erlotinib. The PK of erlotinib was similar between the two cohorts with a median C max of 1.09 versus 0.828 μg/mL and corresponding median AUC 0-t 29.3 versus 30.5 μg h/mL for the AHF and MHI cohorts, respectively. Adverse events from erlotinib in cancer patients with MHI were consistent with the known safety profile. Conclusions: The PK and safety profiles of erlotinib in patients with MHI were similar to those with AHF. As a result, a reduced starting dose of erlotinib in patients with MHI is not required and treatment should be guided by patients' tolerability.

Original languageEnglish (US)
Pages (from-to)605-612
Number of pages8
JournalCancer chemotherapy and pharmacology
Volume69
Issue number3
DOIs
StatePublished - Mar 1 2012

Keywords

  • Erlotinib
  • Hepatic function
  • Pharmacokinetics
  • Protein binding
  • Safety

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function'. Together they form a unique fingerprint.

  • Cite this

    O'Bryant, C. L., Haluska, P., Rosen, L., Ramanathan, R. K., Venugopal, B., Leong, S., Boinpally, R., Franke, A., Witt, K., Evans, J., Belani, C., Gail Eckhardt, S., & Ramalingam, S. (2012). An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer chemotherapy and pharmacology, 69(3), 605-612. https://doi.org/10.1007/s00280-011-1733-6